Merck details win for Keytruda in bladder cancer after surgery

Merck’s top-selling cancer drug Keytruda cut the risk of bladder cancer coming back or death after surgery by 31%, according to new data shared Friday morning.

The Phase III study, known as AMBASSADOR or KEYNOTE-123, included just over 700 patients with urothelial carcinoma — the most common type of bladder…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks